The DEMEL trial evaluated whether melatonin could prevent delirium in mechanically ventilated adults receiving intensive care. It was designed as a multicentre, adaptive randomised trial, reflecting ongoing uncertainty about whether pharmacological sleep support can meaningfully alter delirium risk. Delirium in critical illness is multifactorial. Sleep disruption, inflammation, sedative exposure, immobility, mechanical ventilation and environmental factors all contribute, so a single drug is unlikely to solve the problem on its own. The DEMEL study therefore sits within the broader push toward multimodal delirium prevention and ICU liberation. Its importance for clinicians is that it tests a practical, low-complexity intervention against a clinically important outcome in a population at high risk. The study also illustrates why the conference's delirium sessions appropriately pair pharmacological questions with non-pharmacological strategies such as sleep preservation, early mobility, family involvement and minimisation of unnecessary sedation. For HCPs, melatonin should not be viewed as a substitute for systematic delirium prevention. The most useful clinical approach remains to identify modifiable contributors, regularly assess cognition, optimise day-night cues and mobility, and use sedatives thoughtfully. The trial adds to, rather than replaces, the evidence base for bundled ICU delirium care.